The case for & against
Bull & Bear analysis
Halozyme Therapeutics, Inc. (NASDAQ: HALO) specializes in the development and commercialization of innovative drug delivery platforms, with a primary focus on enhancing biologic therapies via subcutaneous administration. The company's proprietary ENHANZE® platform enables significant changes in how biologics are delivered, making treatments more patient-friendly and thus allowing for wider adoption in therapeutic areas like oncology. Halozyme has established itself as a leader in the biopharma sector, increasingly recognized for its advanced delivery technologies and a strong portfolio of strategic partnerships.
Bull says
- ↑Total revenue +42% YoY to $377M driven by 43% royalty growth
- ↑Adjusted EBITDA +42% to $230M indicates exceptional margins and cash flow
- ↑Initiated $1B buyback with $400M earmarked for 2026 underscores confidence
- ↑Multiple pipeline launches through 2029+ support >30% royalty growth
- ↑High earnings yield and strong profitability factors enhance valuation
- ↑Moderate Buy rating, $81.60 PT, and >97% institutional ownership bolster outlook
Bear says
- ↓Negative book-to-price valuation and weak dividend yield suggest overvaluation
- ↓Balance sheet flagged by leverage risk may limit financial flexibility
- ↓High short interest indicates negative sentiment and potential price drag
- ↓Regulatory approval delays could defer key launch revenues
- ↓Heavy reliance on Darzalex royalties risks sharp revenue swings
- ↓Intensifying competition in delivery tech threatens long-term moat
Investment themes with HALO
Companies repurchasing their own shares
Genetic and drug innovations driving medical breakthroughs
Services and products for aging population
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Revenue increased approximately 42% to $376.7 million compared to $264.9 million in the prior year period. This performance was driven by broad-based strength across the business, including strong growth in royalty revenue and higher product sales to partners.
- Royalty revenue of $240.7 million increased approximately 43% from $168.2 million in the prior year period, reflecting the continued commercial success of key enhanced partner products including subcutaneous Darzalex, 5-GART-Hytrulo, and Fezgo, as well as the continued ramp from recently launched SC therapies, Ocrevus, Opdivo, Ticentric, and Riboprath.
- Adjusted EBITDA increased 42% to $229.5 million from $162 million in the prior year period, driven by continued strong royalty growth.
Bear points
- it is unlikely that we will identify a drug delivery opportunity that meets our criteria to transact on in 2026.
- We're not 100% aware of exactly what Sanofi is doing with regard to a complementary hyaluronidase.
- And that's further informed with some early conversations that partners are having with the FDA who seem to be very much in support with that type of thinking.